Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04459468 · ClinicalTrials.gov registry record
Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC
A clinical trial of Hepatocellular Carcinoma, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 17
- Enrollment target
- 1
- Study location
NCT04459468: Completed study of Hepatocellular Carcinoma, sponsored by University of Texas Southwestern Medical Center.
NCT04459468 is a study of Hepatocellular Carcinoma that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 17 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04459468, a study of Hepatocellular Carcinoma, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will enroll patients with hepatocellular carcinoma being planned for TACE or other standard of care treatment (such as denovo ablation or Y90) and obtain blood samples pre and post treatment procedure for biomarker identification using bead based X-aptamer library. No intervention is planned.
Primary Outcome
X-aptamer identified biomarker to predictability for tumor response rate after treatment with Lipoidol TACE compared to standard of care biomarkers-AFP.
Conditions Studied
Interventions
- DRUG Lipiodol
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2022-11-04 |
| Est. Completion | 2025-09-23 |
What the finished NCT04459468 record still lists
NCT04459468 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Lipiodol is the first listed.
NCT04459468 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04459468 about?
NCT04459468 is a clinical study titled "Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC". This study will enroll patients with hepatocellular carcinoma being planned for TACE or other standard of care treatment (such as denovo ablation or Y90) and obtain blood samples pre and post treatment procedure for biomarker identification using bead based X-aptamer library. No intervention is plan...
What is the current status of trial NCT04459468?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2022-11-04. Estimated completion is 2025-09-23.
What conditions does trial NCT04459468 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT04459468?
The interventions under investigation include: Lipiodol (DRUG).
Who is sponsoring clinical trial NCT04459468?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04459468 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04459468's enrollment target sits among peer trials
17 133rd of 145 higher than 13 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI